Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928226 · ClinicalTrials.gov registry record · NA
Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT00928226: Completed NA study, sponsored by Stanford University.
NCT00928226 is a NA study that has completed, run by Stanford University. The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00928226, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
The maximum tolerated dose of 3-session (ie, treatment) stereotactic radiosurgery (SRS) to treat brain metastases greater than 4.2 cm³ in size will be determined. This study investigates if increasing radiation dose improves outcome for patients without greater toxicity (side effects).
Interventions
- PROCEDURE Surgical resection
- RADIATION Fractionated Stereotactic Radiosurgery (SRS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2009-04 |
| Est. Completion | 2019-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00928226
The ClinicalTrials.gov registry entry for NCT00928226 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Surgical resection is the first listed.
NCT00928226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00928226 about?
NCT00928226 is a clinical study titled "Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases". The maximum tolerated dose of 3-session (ie, treatment) stereotactic radiosurgery (SRS) to treat brain metastases greater than 4.2 cm³ in size will be determined. This study investigates if increasing radiation dose improves outcome for patients without greater toxicity (side effects).
What is the current status of trial NCT00928226?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2009-04. Estimated completion is 2019-12.
What interventions are being tested in trial NCT00928226?
The interventions under investigation include: Surgical resection (PROCEDURE), Fractionated Stereotactic Radiosurgery (SRS) (RADIATION).
Who is sponsoring clinical trial NCT00928226?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.